GENERAL CATALOGUE
DOTA-CXCR4-L
HY-P5297 · 50 mg
MedChemExpress · Cat: HY-P5297
Reach 3+ verified distributors
Manufacturer product page
medchemexpress.com/dota-cxcr4-l.html
Sponsored
Catalog No: HY-P5297
Category: Antibody-drug Conjugate ADC Related
Pack Size: 50 mg
Brand: MedChemExpress
Description
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with 68Ga / 177Lu for the synthesis/research of Radionuclide-Drug Conjugates RDCs .
More from MedChemExpress
Rha-PEG3-SMCC
HY-142740
Antibody-drug Conjugate ADC Related
PPC-NB
HY-126530
Antibody-drug Conjugate ADC Related
Taltobulin intermediate-8
HY-41070
Antibody-drug Conjugate ADC Related
m-PEG8-NHS ester
HY-W019793
Antibody-drug Conjugate ADC Related
Mal-amido-PEG5-C2-NHS ester
HY-126508
Antibody-drug Conjugate ADC Related
Tisotumab vedotin
HY-152963
Antibody-drug Conjugate ADC Related
Muscotoxin A
HY-131058
Antibody-drug Conjugate ADC Related
Methylcyclopropene-PEG4-NHS
HY-136048
Antibody-drug Conjugate ADC Related